Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1017MR)

This product GTTS-WQ1017MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1017MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ99MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ15736MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ13229MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ6007MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO 095
GTTS-WQ5826MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ12531MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ5662MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ2553MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW